Durata Therapeutics Now Covered by Analysts at MLV (DRTX)
Research analysts at MLV started coverage on shares of Durata Therapeutics (NASDAQ:DRTX) in a report released on Friday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
A number of other firms have also recently commented on DRTX. Analysts at MLV & Co
initiated coverage on shares of Durata Therapeutics in a research note on Thursday. They set a “buy” rating and a $21.00 price target on the stock. Separately, analysts at Summer Street initiated coverage on shares of Durata Therapeutics in a research note on Wednesday, April 9th. They set a “buy” rating and a $22.00 price target on the stock. Finally, analysts at Roth Capital raised their price target on shares of Durata Therapeutics from $20.00 to $21.00 in a research note on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $18.38.
In other Durata Therapeutics news, Director Schutter Richard De bought 15,000 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average cost of $15.57 per share, for a total transaction of $233,550.00. Following the transaction, the director now directly owns 15,000 shares in the company, valued at approximately $233,550. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Durata Therapeutics (NASDAQ:DRTX) opened at 16.01 on Friday. Durata Therapeutics has a 52 week low of $6.70 and a 52 week high of $17.20. The stock’s 50-day moving average is $13.99 and its 200-day moving average is $12.81. The company’s market cap is $426.5 million.
Durata Therapeutics (NASDAQ:DRTX) last released its earnings data on Thursday, May 8th. The company reported ($0.62) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.64) by $0.02. Analysts expect that Durata Therapeutics will post $-2.42 EPS for the current fiscal year.
Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.